Regulator restricts use of SSRIs in children

This News article by Lynn Eaton (BMJ 2005;330:984, 30 Apr) contained two inaccuracies about the drug atomoxetine. The manufacturer, Lilly, points out that we wrongly suggested that atomoxetine is an antidepressant (whereas it has no antidepressant activity). Also, atomoxetine is not associated with an increased incidence of suicide related behaviour (as we implied), although it is associated with an increased risk of hostility (as we stated) and emotional lability.